Medicrea International SA Short ratio
What is the Short ratio of Medicrea International SA?
The Short ratio of Medicrea International SA is N/A
What is the definition of Short ratio?
Short ratio is the number of shares sold short divided by the average daily volume.
= short interest / average daily volume
Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.
The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.
What does Medicrea International SA do?
Medicrea International SA designs, manufactures, and distributes spinal implants in France and internationally. It offers PASS range, a polyaxial spine system; PASS LP, a thoraco-lumbar fixation system; LigaPASS, a band connector for posterior thoracolumbar fixation; PASS TULIP, a top loading posterior fixation system; PASS DEGEN for thoracic and lumbar degenerative indications; PASS OCT, an occipito-cervico-thoracic fixation system; PASS MIS, a posterior anchoring system; PASS Antérieur that offers a range of specific implants enabling surgery using an anterior approach; IMPIX C, a sterile PEEK Optima cervical interbody device; IMPIX-C+, a sterile PEEK Optima cervical interbody device that is prefilled with bone substitute; and IMPIX-MANTA, a sterile PEEK Optima cervical interbody device that is preassembled on holder/ impactor and delivers with a disposable instrumentation kit. Its implants for cervical spine also include IMPIX-MANTA +, a sterile PEEK Optima cervical interbody device, which is prefilled with synthetic bone substitutes; and GRANVIA-C, a MRI compatible ceramic cervical disc. In addition, it provides implants for the thoracic and lumbar spine, such as IMPIX-L, a sterile PEEK Optima lumbar interbody device for posterior approach; IMPIX-TLIF, a sterile PEEK Optima lumbar interbody device for transforaminal approach with a pre-assembled PEEK control lead; IMPIX-ALIF, a sterile PEEK Optima lumbar interbody device for anterior approach; STABOLT, an anatomically-shaped anterior plate; OSMOSYS, a macroporous bone substitute; IMPIX-DLIF and IMPIX-DLIF SLIM sterile PEEK Optima lumbar interbody devices for direct or oblique lateral approach; and X-JAWS, a titanium lumbar staple to secure a lateral or an anterior cage. Its implants are designed to treat scoliosis, degenerative diseases, malformations, trauma, and tumors; and used in various traditional and surgical procedures. The company was founded in 1990 and is headquartered in Rillieux-la-Pape, France.